Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
The recommended phase 2 doses of molecularly targeted agents, determined by using an ordinal dose-finding method that only uses toxicity data at first cycle, may not be optimal. Some researchers have proposed the use of relative dose intensity that can account for late-onset, cumulative, and low-gra...
Main Authors: | Akihiro Hirakawa, Yuichi Tanaka, Shuhei Kaneko |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | Contemporary Clinical Trials Communications |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865419302510 |
Similar Items
-
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.
by: Christophe Le Tourneau, et al.
Published: (2012-01-01) -
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
by: Bernard North, et al.
Published: (2019-06-01) -
Phase I dose-escalation oncology trials with sequential multiple schedules
by: Burak Kürsad Günhan, et al.
Published: (2021-04-01) -
Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
by: Gattoc L, et al.
Published: (2016-12-01) -
Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
by: Gattoc, Leda, et al.
Published: (2016)